Grant of share options


 

TIDMCRYO 
 
RNS Number : 9863K 
Cryo-Save Group NV 
29 April 2010 
 

29 April 2010 
 
Cryo-Save Group N.V. 
 
Grant of share options 
 
Cryo-Save Group N.V. (AIM/Euronext: CRYO, 'Cryo-Save' or 'the Group'), Europe's 
leading stem cell bank, announces that on 28 April 2010 the Group granted 
options to subscribe for ordinary shares in the Company under the Cryo-Save 
Group 2009 Share Option Scheme. 
 
The Company granted 20,000 options to Arnoud van Tulder, Chief Financial 
Officer, and 34,000 options to certain other employees of the Group all at an 
exercise price of EUR5.81 per share, being the price equal to the arithmetic 
average of the closing mid-market price over the five dealing days prior to the 
date of the grant. All of these options are exercisable at any time from 29 
April 2013 until 29 April 2020. 
 
The Company now has a total of 204,000 options over ordinary shares outstanding. 
 
 
Enquiries: 
 
+-------------------------------------+---------------------+ 
| Cryo-Save Group                     | +  31 (0)575 548998 | 
+-------------------------------------+---------------------+ 
| Marc Waeterschoot, Chief Executive  |                     | 
+-------------------------------------+---------------------+ 
| Arnoud van Tulder, Chief Financial  |                     | 
| Officer                             |                     | 
+-------------------------------------+---------------------+ 
|                                     |                     | 
+-------------------------------------+---------------------+ 
| Daniel Stewart & Company plc        |     + 44 (0)20 7776 | 
|                                     |                6550 | 
+-------------------------------------+---------------------+ 
| Simon Leathers/Emma Earl            |                     | 
+-------------------------------------+---------------------+ 
|                                     |                     | 
+-------------------------------------+---------------------+ 
| College Hill (UK)                   |     + 44 (0)20 7457 | 
|                                     |                2020 | 
+-------------------------------------+---------------------+ 
| Adrian Duffield/Rozi Morris         |                     | 
+-------------------------------------+---------------------+ 
|                                     |                     | 
+-------------------------------------+---------------------+ 
| SPJ Financiële Communicatie         |  +31 (0)20 647 8181 | 
| Amstelveen (NL)                     |                     | 
+-------------------------------------+---------------------+ 
| Kees Jongsma/Léon Melens            |                     | 
+-------------------------------------+---------------------+ 
 
 
About Cryo-Save 
 
With more than 120,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world. Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCIPMATMBITBRM

Cryo-Save (LSE:CRYO)
過去株価チャート
から 12 2024 まで 1 2025